medigraphic.com
ISSN 1405-1710 (Impreso)

2019, Número 2

<< Anterior Siguiente >>

Rev Cent Dermatol Pascua 2019; 28 (2)


Lupus eritematoso cutáneo subagudo tipo anular. Presentación de un caso

López-Cepeda LD, Martínez EV, González GM, Hernández BB, García AMJ

Idioma: Español
Referencias bibliográficas: 32
Paginas: 71-75
Archivo PDF: 336.27 Kb.


RESUMEN

El lupus eritematoso es una enfermedad autoinmunitaria que puede tener expresión sistémica o cutánea; de la forma cutánea se clasifica en tres subgrupos, dentro de los que se encuentra el cutáneo subagudo, el cual a su vez, tiene a la variante anular. En el presente artículo, comunicamos el caso de una paciente con esta variedad clínica en el rostro, que es poco frecuente y con resolución satisfactoria.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lee LA, Werth VP. Lupus erythematosus. In: Bolognia JL, Jorizzo JL, Rapini RP et al (Eds.). Dermatology. 3rd ed. Elsevier Limited; 2012. p. 615.

  2. Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013; 12: 444-454.

  3. Shinada S, Wallace DJ. Laboratory features of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T (Eds.). Cutaneous lupus erythematosus. Heidelberg: Springer, Berlin; 2005. pp. 311-322.

  4. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25- year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005; 4: 253- 263.

  5. Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2005; 166: 29-35.

  6. Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003; 4: 449-465.

  7. Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol. 2000; 115: 726-730.

  8. Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007; 33: 85-106.

  9. Kim GK, Del Rosso JQ. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Yearbook of Dermatology and Dermatologic Surgery; 2012. pp. 224-225.

  10. Yu C, Chang C, Zhang J. Immunologic and genetic considerations of cutaneous lupus erythematosus: a comprehensive review. J Autoimmun. 2013; 41: 34-45.

  11. Chavarría E, Bueno C, Lázaro P, Lecona M. Lupus eritematoso sistémico de presentación cutánea subaguda. Presentación de dos casos clínicos. Actas Dermosifiliogr. 2005; 96: 248-251.

  12. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014; 48-49: 14-19.

  13. Kim A, Chong BF. Photosensitivity in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2013; 29: 4-11.

  14. Grönhagen C, Nyberg F. Cutaneous lupus erythematosus: An update. Indian Dermatol Online J. 2014;5:7-13.

  15. Sontheimer RD. The lexicon of cutaneous lupus erythematosus- -a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997; 6: 84-95.

  16. Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol. 2002; 138: 1175-1178.

  17. Pretel M, Marqués L, España A. Lupus eritematoso inducido por fármacos. Actas Dermosifiliogr. 2014; 105: 18-30.

  18. Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013; 27: 391-404.

  19. Bolognia-Jean L, Jorizzo-Joseph L, Rapini-Ronald P. Enfermedades reumatológicas. Dermatología. España: Ed Mosby; 2004. pp. 601-604.

  20. Eastham AB, Vleugels RA. Cutaneous lupus erythematosus. JAMA Dermatol. 2014; 150: 344.

  21. Martínez-Estrada V, Hernández-Pérez M, Ramos-Garibay A. Lupus eritematoso cutáneo subagudo tipo psoriasiforme. Rev Cent Dermatol Pascua. 2004; 13: 88-90.

  22. Stavropoulos PG, Goules AV, Avgerinou G, Katsambas AD. Pathogenesis of subacute cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol. 2008; 22: 1281-1289.

  23. Vera C. Manifestaciones específicas del lupus cutáneo. Rev Chil Reumatol. 2001; 27: 222-228.

  24. Moura-Filho JP, Peixoto RL, Martins LG, Melo SD, Carvalho LL, Pereira AK et al. Lupus erythematosus: considerations about clinical, cutaneous and therapeutic aspects. An Bras Dermatol. 2014; 89: 118-125.

  25. Salomón M, Samalvides F, Gordillo J, Gutierrez C. Manifestaciones histopatológicas del lupus eritematoso cutáneo en pacientes del Servicio de Dermatología del Hospital Nacional Cayetano Heredia, 2003-2008. Folia Dermatol Peru. 2009; 20: 64-70.

  26. Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus. 2010; 19: 1036-1046.

  27. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev. 2006; 5: 114-117.

  28. Böhm M, Gaubitz M, Luger TA, Metze D, Bonsmann G. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology. 2003; 207: 381-385.

  29. Kanekura T, Yoshii N, Terasaki K, Miyoshi H, Kanzaki T. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br Jour Dermatol. 2003; 148: 353-356.

  30. Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol. 2006; 24: 348-362.

  31. Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011; 13: 300-307.

  32. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. JAAD. 2011; 65: e179-e193.




2020     |     www.medigraphic.com